Home › Stomach Cancer › New Jersey › Camden
Stomach Cancer clinical trials in Camden, NJ
3 studies for Stomach Cancer are looking for participants at sites in and around Camden (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
- MD Anderson Cancer Center at Cooper, Camden
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Inspira Medical Center Mullica Hill, Mullica Hill · 14 mi away
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RecruitingPhase 3
- Research Site, Camden
About Stomach Cancer
Did you know risk factors for stomach (gastric) cancer include a diet high in salty or smoked food or having an H. pylori infection? Learn more here.
More about Stomach Cancer on MedlinePlus
Stomach Cancer trials in other cities
- Houston, TX44 studies
- New York City, NY33 studies
- Boston, MA32 studies
- Nashville, TN27 studies
- Los Angeles, CA23 studies
- Arlington, VA21 studies
- Baldwin Park, CA21 studies
- Dallas, TX20 studies
- San Antonio, TX20 studies
- Grand Rapids, MI20 studies
- Chicago, IL19 studies
- St. Louis, MO18 studies
Other studies in Camden
- Non-Small Cell Lung Cancer12 studies
- Lung Cancer10 studies
- Schizophrenia9 studies
- Heart Failure8 studies
- Breast Cancer7 studies
- Cancer (all types)7 studies
- Coronary Artery Disease7 studies
- Ovarian Cancer6 studies
- COPD6 studies
- Major Depressive Disorder6 studies
- Cardiovascular Disease6 studies
- High Blood Pressure5 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.